Cuál es el precio por TME Pharma N.V. (ALTME)

Precio por TME Pharma N.V. (ALTME) es de$0.10046734

Cuál es la capitalización de mercado por TME Pharma N.V. (ALTME)

Capitalización de mercado por TME Pharma N.V. (ALTME) es $9.46M

TME Pharma N.V. (ALTME) Desdoblamientos de Acciones

TME Pharma N.V., a biopharmaceutical company in the clinical development stage based in Berlin, Germany, is dedicated to pioneering innovative therapeutic solutions for cancer. The company leverages its unique Spiegelmer platform to advance a pipeline of investigational drug candidates. Its primary oncology asset, NOX-A12, is currently being evaluated in clinical studies as a combination therapy for a range of challenging cancers, including metastatic pancreatic and colorectal cancer, glioblastoma, and myeloma. Beyond its cancer-focused efforts, TME Pharma also developed NOX-E36, which has successfully concluded Phase 1/2 clinical trials for diabetic nephropathy. The company has formed a strategic collaboration with Merck Sharp & Dohme Corp. to explore NOX-A12 in combination with Keytruda and two different chemotherapy protocols as a second-line intervention for patients battling metastatic pancreatic cancer. Founded in 1997, the organization adopted its current name, TME Pharma N.V., in July 2022, having previously operated as NOXXON Pharma N.V.

Año	Desdoblamiento	Multiplicador	Multiplicador acumulado
Not enough data for the provided dates.

Año

Desdoblamiento

Multiplicador

Multiplicador acumulado

Not enough data for the provided dates.

Empresa	Número de desdoblamientos de acciones	Multiplicador acumulado	País
Vertex Pharmaceuticals Incorporated VRTX.US	1	x2	US
Argenx SE ARGX.US	0	-	NL
Lonza Group AG LONN.SW	0	-	CH
Samsung Biologics Co.,Ltd. 207940.KS	0	-	KR
UCB S.A. UCB.BR	0	-	BE

Empresa

Número de desdoblamientos de acciones

Multiplicador acumulado

País